These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21318007)

  • 1. Antimony toxicity.
    Sundar S; Chakravarty J
    Int J Environ Res Public Health; 2010 Dec; 7(12):4267-77. PubMed ID: 21318007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pancreatitis during treatment of leishmaniasis with n-methylglucamine antimoniate in a subject infected with HIV].
    Trinchieri V; Ferone U; Monacelli M; Isceri L; Proietti F; Sorice F
    Riv Eur Sci Med Farmacol; 1996; 18(2):49-51. PubMed ID: 9213843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentavalent antimonials: new perspectives for old drugs.
    Frézard F; Demicheli C; Ribeiro RR
    Molecules; 2009 Jun; 14(7):2317-36. PubMed ID: 19633606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occupational exposure to antimony compounds.
    McCallum RI
    J Environ Monit; 2005 Dec; 7(12):1245-50. PubMed ID: 16307078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Cancer for Workers Exposed to Antimony Compounds: A Systematic Review.
    Saerens A; Ghosh M; Verdonck J; Godderis L
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
    Bourée P; Anciaux ML; Taugourdeau P
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):607-10. PubMed ID: 3003657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability, Toxicology and Medical Significance of Antimony.
    Periferakis A; Caruntu A; Periferakis AT; Scheau AE; Badarau IA; Caruntu C; Scheau C
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of antimony dextran glycoside (RL-712) against visceral leishmaniasis in the hamster.
    Mikhail JW; Khayyal MT; Girgis NI
    Bull World Health Organ; 1969; 40(2):327-8. PubMed ID: 5306550
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral pentoxifylline and pentavalent antimony for treatment of leishmaniasis: promising but inconclusive evidence of superiority, compared with antimony monotherapy.
    Ojha RP; Cervantes D; Fischbach LA
    Clin Infect Dis; 2007 Oct; 45(8):1104; author reply 1005-6. PubMed ID: 17879933
    [No Abstract]   [Full Text] [Related]  

  • 10. Leishmaniasis in HIV infection.
    Paredes R; Munoz J; Diaz I; Domingo P; Gurgui M; Clotet B
    J Postgrad Med; 2003; 49(1):39-49. PubMed ID: 12865570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and efficacy of the antileishmanial drug meglumine antimoniate in the owl monkey (Aotus trivirgatus).
    Chapman WL; Hanson WL; Hendricks LD
    J Parasitol; 1983 Dec; 69(6):1176-7. PubMed ID: 6674468
    [No Abstract]   [Full Text] [Related]  

  • 12. On the toxicity of some organic antimonial drugs used for the treatment of kala-azar.
    BOSE AN; GHOSH TN
    Ind Med Gaz; 1946 Jan; 81(1):13-6. PubMed ID: 21025569
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.
    Berman JD
    Rev Infect Dis; 1988; 10(3):560-86. PubMed ID: 3293160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and toxicological studies of antimony dextran glycoside (RL-712).
    Casals JB
    Br J Pharmacol; 1972 Oct; 46(2):281-8. PubMed ID: 4651773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.
    Badaro R; Falcoff E; Badaro FS; Carvalho EM; Pedral-Sampaio D; Barral A; Carvalho JS; Barral-Netto M; Brandely M; Silva L
    N Engl J Med; 1990 Jan; 322(1):16-21. PubMed ID: 2104665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Case of visceral leishmaniasis in adult treated with N-methylglucamine antimony].
    NAPOLITANO F
    G Med Mil; 1952; 102(6):521-7. PubMed ID: 13034080
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of leishmaniasis (author's transl)].
    Barabe P
    Med Trop (Mars); 1981; 41(6):599-605. PubMed ID: 7339417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative evaluation of effectiveness of antimony preparations in the treatment of visceral leishmaniasis].
    MIRZOIAN NA
    Med Parazitol (Mosk); 1954; 23(2):161-4. PubMed ID: 13175906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.